ARCT-154 (Bivalent)
COVID-19
Key Facts
About Arcturus Therapeutics
Arcturus Therapeutics is a pioneer in mRNA therapeutics, leveraging its differentiated LUNAR® delivery and STARR™ self-amplifying mRNA platforms to create a diverse pipeline targeting infectious diseases, rare genetic disorders, and other therapeutic areas. The company achieved a major milestone with the approval and commercialization of its COVID-19 vaccine in Asia, validating its technology and establishing commercial capabilities. With strategic partnerships, including a major collaboration with CSL, Arcturus is advancing multiple clinical and preclinical programs while exploring the broad potential of its mRNA platform beyond vaccines.
View full company profileOther COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| Remdesivir (Veklury) | Gilead Sciences | Approved |
| mRNA-1273 (Spikevax) | Moderna | Approved |
| Investigational Oral COVID-19 Antiviral | Shionogi | Clinical |
| ZyCoV-D | Zydus Lifesciences | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| SARS-CoV-2 Neutralizing Antibodies | Adaptive Biotechnologies | Discovery |
| Covovax™ | Novavax | Approved/Commercial |
| LY-CoV555 (Bamlanivimab) | AbCellera | Emergency Use Authorization (Past) |
| LUNAR-COV19 (ARCT-021) | Arcturus Therapeutics | Phase 1/2 |
| Paxlovid (Nirmatrelvir) Manufacturing Enzyme | Codexis | Commercial |